Core Viewpoint - Guorui Life (00108) has seen a significant increase in stock price, rising over 42% in the month, with a current price of 3.32 HKD and a trading volume of 1.5621 million HKD [1] Group 1: Acquisition Details - Guorui Life plans to acquire 78.29% of the internet medical platform Chunyu Doctor for approximately 269 million RMB [1] - Chunyu Doctor is a representative enterprise in the early mobile internet medical field in China, with about 180 million registered users and 690,000 contracted physicians as of June 2025 [1] - The platform handles approximately 330,000 health consultations daily and has accumulated around 400 million health records, evolving into a digital hospital and community health service ecosystem [1] Group 2: Strategic Intent - Guorui Life emphasizes Chunyu Doctor's solid customer base and rich experience in the digital medical service sector [1] - The company aims to leverage its existing resources, market position, and relationships to assist Chunyu Doctor in expanding its service range and attracting new users and corporate clients [1] - This strategy is expected to further enhance Chunyu Doctor's business and revenue growth [1]

Core Viewpoint - Ark Health (06086) has seen a significant stock increase of nearly 40%, currently trading at 3.21 HKD, following the announcement of a collaboration with Tencent Health on an "AI + Chronic Disease Management" solution, marking a new development phase in the domestic chronic disease management sector [1] Group 1: Company Collaboration - The partnership between Ark Health and Tencent Health aims to provide comprehensive support for industry partners, from technology validation to scenario implementation and large-scale deployment, injecting new momentum into the intelligent, compliant, and efficient development of the industry [1] - Ark Health, as a leading "AI + Chronic Disease Management" service platform in China, leverages its innovative "AI + H2H (Hospital to Home) smart medical ecosystem" to establish unique technological advantages and practical experience in chronic disease management [1] - Tencent Cloud, recognized as a leading cloud service provider, excels in key technology areas such as cloud computing, big data, and artificial intelligence, enhancing the partnership's capability to support the digital upgrade of the "AI + Chronic Disease Management" field [1] Group 2: Industry Context - This collaboration represents not only a systematic output of technical capabilities but also an important exploration of the deep integration model of "Artificial Intelligence + Healthcare" [2] - In response to recent policy initiatives from the National Health Commission and other departments promoting the application of "Artificial Intelligence + Healthcare," the partnership aligns with national efforts to advance the healthy development of the AI healthcare industry [2]

阿里健康、阿里巴巴涨近5%，小鹏汽车涨超4%，比亚迪股份涨超3%。 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 风险提示及免责条款 ...

▲南宁市以互联网及信息技术为依托，建设"南宁云医院"平台。 ■本报记者廖欣 罗屹钦 "李奶奶，早上好！我来为您做检查了。"近日，在青秀区中山路东二里一居民家中，95岁的李奶奶躺在床上，护士刘丽霞轻声问候，随后俯身给李奶奶量血 压、消毒、静脉采血，动作娴熟而轻柔。这温情一幕，正是南宁市大力打造"南宁云医院"平台，破解群众就医难题的生动缩影。 随着老龄化进程加快，术后康复、老年照护、慢病管理等需求日益增长。对于行动不便的老人、失能人群和母婴人群来说，出门就医成为一大难题。作为广 西首个"互联网+护理"服务试点城市，自2022年以来，南宁市以互联网及信息技术为依托，建设"南宁云医院"平台，构建涵盖医、护、药的"互联网+健康医 ▶在南宁市中医医院新华院区，妇科副主任医师明珠通过"南宁云医院"平台为市民提供线上问诊服务。 本报记者廖欣 摄 小平台托举大民生。记者从南宁市卫生健康委员会了解到，目前全市有84家医疗机构超3300名医生、超6700名护士入驻"南宁云医院"平台，提供超过180项 线上线下服务。平台按"就近匹配+双模式派单"调度，确保15分钟服务半径覆盖。 "能上门服务的护士，都是经过严格筛选的。"刘丽霞介绍， ...

Core Insights - Ping An Good Doctor and Yimai Qingteng signed a cooperation agreement to enhance AI technology in medical services, focusing on intelligent recommendations and diagnostic assistance [1][4] - The partnership aims to create a seamless healthcare service loop, ensuring accessibility, reliability, and continuity in health management [1][3] Group 1: Company Collaboration - The collaboration will leverage Yimai Qingteng's expertise in medical imaging to enhance Ping An Good Doctor's service system, which includes "to line, to hospital, to home, and to enterprise" [3][5] - Both companies will explore AI-assisted medical applications, aiming for deep integration across the entire healthcare process from diagnosis to management [4][5] Group 2: Industry Context - The partnership aligns with the "Healthy China 2030" national strategy, addressing the evolving health needs of the population for integrated, human-centered solutions [5] - The collaboration is seen as a significant step towards overcoming industry challenges such as uneven resource distribution and fragmented service chains, enhancing user experience in healthcare [5]

Core Viewpoint - The newly launched Hong Kong Stock Connect Medical ETF by Huabao (159137) is expected to perform actively due to the rising interest in the medical sector and favorable market conditions, coinciding with a strong performance in both the Hong Kong and A-share medical sectors at the beginning of 2026 [1][2]. Group 1: ETF Launch and Market Context - The Hong Kong Stock Connect Medical ETF Huabao (159137) was established on December 31, 2025, and began trading on January 12, 2026 [2]. - The underlying index, the "CSI Hong Kong Stock Connect Medical Theme Index," has seen a 14.25% increase from January 1 to January 9, 2026, and a total annual increase of 48.20% in 2025, indicating a strong recovery in the Hong Kong medical sector [2][4]. - The ETF's launch coincides with a rare "sixteen consecutive days of gains" in the Shanghai Composite Index, reflecting heightened investor enthusiasm [1]. Group 2: Investment Strategy and Composition - The ETF covers four major sectors within the Hong Kong medical field: CXO, medical business and services, medical devices, and biopharmaceuticals, with over 80% of its weight concentrated in leading companies in CXO, internet healthcare, and high-end medical devices [2][4]. - The top ten constituents of the index include major players such as WuXi Biologics (15.28% weight), JD Health (11.84%), and Alibaba Health (5.42%), collectively accounting for 63.89% of the index [4]. Group 3: Market Potential and Valuation - The Hong Kong medical sector is characterized by significant growth potential, driven by an aging population and increasing healthcare demands, with the CXO market expected to grow at a CAGR of 26.56% from 2020 to 2025 [4]. - The index's valuation remains relatively low, with a TTM P/E ratio of 29.43, which is below historical averages, suggesting a favorable entry point for investors [5].

Core Viewpoint - The newly launched Hong Kong Stock Connect Medical ETF, Huabao (159137), is expected to perform actively due to the rising interest in the medical sector and favorable market conditions, coinciding with the recent recovery of the Hong Kong and A-share medical sectors at the beginning of 2026 [1][14]. Group 1: ETF Launch and Market Context - The Hong Kong Stock Connect Medical ETF Huabao (159137) was established on December 31, 2025, and began trading on January 12, 2026 [1][15]. - The Shanghai Composite Index has recently shown a rare "sixteen consecutive days of gains," surpassing the 4100-point mark, indicating high investor enthusiasm [1][14]. - The Hong Kong Stock Connect Medical Theme Index has increased by 14.25% from January 1 to January 9, 2026, and had an annual increase of 48.20% in 2025, reflecting a significant recovery in the medical sector [1][15]. Group 2: ETF Composition and Investment Focus - The ETF tracks the CSI Hong Kong Stock Connect Medical Theme Index, covering four major areas: CXO, medical business and services, medical devices, and biopharmaceuticals, with over 80% of its weight concentrated in leading companies in CXO, internet healthcare, and high-end medical devices [2][15]. - More than 85% of the ETF's components are "Hong Kong exclusive" stocks, including unique offerings like JD Health and Alibaba Health, which provide investors with significant opportunities in the Hong Kong medical sector [2][15]. Group 3: Market Potential and Valuation - The Hong Kong medical sector is characterized as a "golden track" with substantial market potential, driven by an aging population and increasing healthcare demand, supported by a growing GDP per capita [4][19]. - The CSI Hong Kong Stock Connect Medical Theme Index is currently at a historical low, with a drop of over 65% from its peak in 2021, and a price-to-earnings ratio (TTM) of 29.43, which is below 65% of its historical range [6][19]. - The index's configuration offers a compelling cost-performance ratio, making the ETF a noteworthy investment tool for investors [6][19].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公 司註冊處處長登記前，不會向香港公眾人士提出要約或邀請。倘於適當時候向 香港公眾人士提出要約或邀請，有意投資者務請僅依據與香港公司註冊處處 長登記的本公司招股章程作出投資決定，招股章程副本將於發售期內向公眾 人士提供。 We Doctor Holdings Limited 微醫控股有限公司 （於英屬維爾京群島註冊成立的有限公司並以存續方式於開曼群島註冊） 警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委 員會（「證監會」）的要求而刊發，僅用作向香港公眾人士提供資料。 閣下閱覽本公告，即表示 閣下知悉、接納並向微醫控股有限公司（「本公司」）、 其保薦人、整體協調人、顧問或包銷團成員表示同意： – 2 – (e) 本公告（及其所載資料）僅供參考，並不構成或組成在美國（包括其領土及 屬地、美國任何州及哥倫比亞特區） ...

Market Performance - The Hong Kong stock market saw all three major indices rise on January 9, with the Hang Seng Index increasing by 0.32% to close at 26,231.79 points [1][3] - The Hang Seng Technology Index rose by 0.15% to 5,687.14 points, while the National Enterprises Index increased by 0.1% to 9,048.53 points [1][3] Sector Performance - Internet healthcare stocks performed well, with Alibaba Health leading the gains at 4.72%, and Ping An Good Doctor and JD Health both rising over 2.9% [3] - Gold stocks collectively surged, with Shandong Gold rising by 6.12%, and Zhaojin Mining and Lingbao Gold also seeing increases [3] - Non-ferrous metal stocks also moved upward, with Luoyang Molybdenum rising by 4.74%, and China Aluminum and Jiangxi Copper both increasing by over 2% [3] - Apple concept stocks were all in the green, with Lens Technology soaring by 9.01%, and Sunny Optical Technology experiencing slight gains [3] Weekly Market Trends - The Hong Kong stock market exhibited a pattern of "opening strong followed by fluctuations" during the week, with the Hang Seng Index reaching a peak of 26,858.13 points on January 6, marking the highest level since November 14 of the previous year [3] - The Hang Seng Technology Index mirrored this trend, hitting a daily high of 5,875.32 points, also the highest since November 14, 2025 [3] Economic Indicators - Market analysts provided positive interpretations of the rebound in the Hong Kong stock market on January 9, attributing it to favorable economic data from mainland China [3] - The latest Consumer Price Index (CPI) showed a year-on-year increase of 0.8%, meeting expectations, while the Producer Price Index (PPI) also showed improvement, contributing to the market's slight rebound [3]

Group 1 - Morgan Stanley reduced its stake in Alibaba Health (00241) by 23.467799 million shares at a price of 5.5024 HKD per share, totaling approximately 129 million HKD [1] - After the reduction, the latest number of shares held by Morgan Stanley is approximately 1.291 billion shares, representing a holding percentage of 7.97% [1]